MYnd Analytics, Inc. (MYND) Is At $2.27 Formed Wedge; Ardelyx, Inc. (ARDX) Covered By 7 Bulls

Ardelyx, Inc. (NASDAQ:ARDX) Logo

MYnd Analytics, Inc. (MYND) formed wedge down with $2.11 target or 7.00% below today’s $2.27 share price. MYnd Analytics, Inc. (MYND) has $9.89 million valuation. The stock increased 0.74% or $0.0166 during the last trading session, reaching $2.2666. About 188,480 shares traded or 22.70% up from the average. MYnd Analytics, Inc. (NASDAQ:MYND) has declined 82.06% since April 25, 2017 and is downtrending. It has underperformed by 93.61% the S&P500.

Among 7 analysts covering Ardelyx Inc (NASDAQ:ARDX), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ardelyx Inc had 16 analyst reports since August 18, 2015 according to SRatingsIntel. The rating was maintained by Cantor Fitzgerald with “Buy” on Monday, August 28. The firm has “Buy” rating given on Friday, October 13 by BTIG Research. On Friday, October 13 the stock rating was maintained by Citigroup with “Buy”. The stock of Ardelyx, Inc. (NASDAQ:ARDX) earned “Buy” rating by Cantor Fitzgerald on Wednesday, May 31. The firm has “Buy” rating by Cantor Fitzgerald given on Friday, March 16. The stock has “Buy” rating by BTIG Research on Friday, December 18. The company was initiated on Tuesday, September 22 by BTIG Research. Cantor Fitzgerald maintained it with “Overweight” rating and $14 target in Thursday, October 12 report. The rating was maintained by Wedbush on Thursday, October 12 with “Buy”. JMP Securities maintained the stock with “Market Outperform” rating in Wednesday, March 9 report. See Ardelyx, Inc. (NASDAQ:ARDX) latest ratings:

16/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $12.0 Maintain

The stock increased 1.08% or $0.05 during the last trading session, reaching $4.7. About 407,120 shares traded or 25.64% up from the average. Ardelyx, Inc. (NASDAQ:ARDX) has declined 60.67% since April 25, 2017 and is downtrending. It has underperformed by 72.22% the S&P500.

Ardelyx, Inc. develops and sells therapeutics for the treatment of cardio renal and gastrointestinal diseases in the United States. The company has market cap of $223.74 million. The Company’s lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It currently has negative earnings. The firm is also developing RDX7675, which is in Phase III clinical trial for the treatment of people with hyperkalemia; and RDX8940 in Phase I clinical trial for the treatment of patients with NASH and other gastrointestinal indications.

Ardelyx, Inc. (NASDAQ:ARDX) Ratings Chart